Version July 2025
| Vaccine | Before pregnancy | During pregnancy | After pregnancy | Type of vaccine |
| Haemophilus influenzae | Yes, if indicated | Yes, if indicated | Yes, if indicated | Inactivated |
| Hepatitis A | Yes, if indicated | Yes, if indicated | Yes, if indicated | Inactivated |
| Hepatitis B | Yes, if indicated | Yes, if indicated | Yes, if indicated | Inactivated |
| HPV | Yes, if indicated | No, delay until after pregnancy, if indicated | Yes, if indicated | Inactivated |
| Influenza | ||||
| Yes | Yes | Yes | Inactivated |
| Yes, if less than 50 years of age and healthy; avoid conception for 4 weeks | No | Yes, if less than 50 years of age and healthy; avoid conception for 4 weeks | Live |
| Meningococcal | ||||
| Yes, if indicated | Yes, if indicated | Yes, if indicated | Inactivated |
| Yes, if indicated | No, delay until after pregnancy, if indicated¶ | Yes, if indicated | Inactivated |
| Yes, if indicated | No, delay until after pregnancy, if indicated¶ | Yes, if indicated | Inactivated |
| MMR | Yes, if indicated, avoid conception for 4 weeks | No | Yes, if indicated, give immediately postpartum if susceptible to rubella | Live |
| Mpox | ||||
| Yes, if indicated | Yes, if indicated | Yes, if indicated | Live, non-replicating |
| Yes, if indicated, avoid conception for 4 weeks | No | Yes, if indicated | Live |
| Pneumococcal | ||||
| Yes, if indicated | Yes, if indicated | Yes, if indicated | Inactivated |
| Yes, if indicated | Yes, if indicated | Yes, if indicated | Inactivated |
| RSV¶Δ | No | Yes | No | Inactivated |
| SARS-CoV-2 | Yes | Yes | Yes | Inactivated |
| Tdap | Yes, if indicated | Yes, vaccinate in each pregnancy ideally between 27 and 36 weeks of gestation | Yes, immediately postpartum, if not received previously | Toxoid/inactivated |
| Td | Yes, if indicated | Yes, if indicated, Tdap preferred | Yes, if indicated | Toxoid |
| Varicella | Yes, if indicated, avoid conception for 4 weeks | No | Yes, if indicated, give immediately postpartum if susceptible | Live |
| Varicella-zoster | ||||
| Yes, if indicated | No, delay until after pregnancy, if possible | Yes, if indicated | Inactivated |
| Yes, if indicated and RSV is not available, avoid conception for 4 weeks | No | Yes, if indicated | Live |
ACAM2000: live replication-competent smallpox vaccine; HPV: human papillomavirus; IIV: inactivated influenza vaccine; LAIV: live attenuated influenza vaccine; MMR: measles, mumps, and rubella vaccine; MVA: modified vaccinia Ankara; RSV: respiratory syncytial virus; RZV: recombinant zoster vaccine; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; Tdap: tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine; Td: tetanus and diphtheria toxoid vaccine; ZVL: zoster live vaccine.
* Confirm that LAIV is a recommended option for influenza vaccination each season.
¶ Delay MenB and MenABCWY until after pregnancy unless at increased risk and vaccination benefit outweighs uncertain risks.
Δ Pregnant individuals are vaccinated with the inactivated nonadjuvanted recombinant RSV vaccine (RSVPreF; Abrysvo) between 32 to 37 weeks of gestation if the infant is expected to be born during RSV season. Repeat doses are not recommended in subsequent pregnancies. When RSV is not administered during pregnancy, RSV monoclonal antibody (nirsevimab) should be administered to the neonate instead. This is discussed in other UpToDate content.
◊ ZVL is not available in the United States.
